PixerLens and Tata Consultancy Services Partner to Deliver AI-Powered Application Intelligence on TCS SovereignSecure Cloud
PLEASANTON, Calif., April 23, 2026 /PRNewswire/ -- PixerLens, Inc. announces a strategic…
HashKey Cloud Partners with EAG to Support the Ethereum Application Ecosystem through ETH Staking
HONG KONG, April 20, 2026 /PRNewswire/ -- HashKey Cloud, the digital asset…
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
April 10, 2026 17:02 ET | Source: Replimune, Inc. WOBURN, Mass., April…
Aikido Receives the 2026 Global Application Security Posture Management Customer Value Leadership Recognition for Excellence in Developer-First Security Innovation
This company is recognized for continuous innovation, strategic partnerships, and strong customer…
Polaroid Therapeutics (PTx) Receives CE Mark for POLTX_Fiber: the first application of APT to launch a new standard in wound care
Introducing Antimicrobial Polymer Technology (APT™) in POLTX_Fiber™, a Class IIb advanced wound…
ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options
Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye…
U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the…
Tower Capital Asia announces majority investment in V-Key – a leader in digital identity and mobile application security
SINGAPORE, Feb. 12, 2026 /PRNewswire/ -- Tower Capital Asia ("TCA") is pleased…
Mitsubishi Electric and Landis+Gyr Accelerate Grid Edge Innovation as Mitsubishi Electric Takes Part in Landis+Gyr’s Application Ecosystem
ATLANTA and TOKYO, Jan. 27, 2026 /PRNewswire/ -- Mitsubishi Electric Corporation and…
FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment…
